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Differential effects of 19-nor-1,25-(OH)2D2 and 1-hydroxy- Secondary hyperparathyroidism is a common complica-
vitamin D2 on calcium and phosphorus in normal and uremic tion in patients with chronic renal failure. 1,25-(OH)2D3,
rats. the most active metabolite of vitamin D, controls para-Background. Calcitriol, 1,25-(OH)2D3 (1,25D), the most ac-
thyroid gland growth and suppresses the synthesis andtive metabolite of vitamin D, has been used in the treatment
secretion of parathyroid hormone (PTH) [1–4]. Severalof secondary hyperparathyroidism (SH) because it controls
parathyroid gland growth and suppresses parathyroid hormone investigators have reported the efficacy of intravenous
(PTH) synthesis and secretion. Due to the calcemic and phos- administration of 1,25-(OH)2D3 in suppressing PTH lev-phatemic actions of 1,25D, two analogs with potentially less els in hemodialysis patients [5–9]. Its effectiveness, how-side effects, 19-nor-1,25-(OH)2D2 (19-nor) and 1(OH)D2 (1D2)
ever, is often precluded by the development of hypercal-are currently being used in the treatment of SH.
cemia and/or hyperphosphatemia due to the potentMethods. This study compares the effects of these two ana-
logs on calcium (Ca) and phosphorus (P) metabolism in normal, action of 1,25-(OH)2D3 on intestinal calcium and phos-
uremic, and parathyroidectomized (PTX) rats. Using doses of phorus absorption and bone mineral resorption. In addi-
50 to 250 ng of 19-nor or 1D2, experiments were conducted tion, hyperphosphatemia is a persistent problem in pa-in normal and uremic rats.
tients on chronic hemodialysis, and the use of calciumResults. In uremic rats, 19-nor did not increase plasma Ca
or P while 1D2 caused a dose-dependent increase in both. In acetate or calcium carbonate as a phosphate binder only
addition, while the Ca  P product remained unchanged in increases the risk of hypercalcemia from 1,25-(OH)2D3
19-nor-treated rats, it increased progressively with 1D2 admin- therapy [10]. The recent development of vitamin D ana-
istration. In metabolic studies in normal rats treated with vehi-
logs that retain many of the therapeutic properties ofcle, 10 ng of 1,25D, 100 ng of 19-nor or 100 ng 1D2, intestinal
1,25-(OH)2D3 but have less calcemic and phosphatemiccalcium absorption and urinary calcium excretion were signifi-
cantly higher in 1D2–treated rats compared to those receiving activity has been a major advancement in vitamin D
19-nor. Similar results were seen for intestinal phosphorus ab- therapies [11–13]. Some of these vitamin D analogs dis-
sorption and urinary phosphorus excretion. Finally, the skeletal play high differentiating and antiproliferative activities
response to these two analogs was tested in PTX rats fed a
in leukemic cells, breast cancer cells and psoriatic fibro-calcium-deficient diet and treated daily with 100 ng of 19-nor
blasts and keratinocytes [14–21] as well as modulate theor 1D2. The increase in plasma calcium in 1D2–treated rats
was markedly higher than in those receiving 19-nor. Similar immune system [22]. In addition, these analogs seem to
results were seen in plasma phosphorus when these studies have less of an effect on mineral metabolism at their
were repeated using a phosphorus-deficient diet. effective doses.
Conclusions. These studies demonstrate that when given in
Previous studies from our laboratory demonstrated thatlarge doses to rats 19-nor is less calcemic and phosphatemic
19-nor-1,25-(OH)2D2 (19-nor), an analog of 1,25-(OH)2D3,than 1D2. The lower Ca  P product in 19-nor treated rats
may be an important consideration in patient therapy. Further suppresses PTH levels in uremic rats at doses that did
studies in patients are necessary to define the clinical applicabil- not increase plasma ionized calcium levels [23, 24]. More-
ity of these differences. over, in contrast to 1,25-(OH)2D3, 19-nor had no effect
on plasma phosphorus levels. 19-nor (Zemplar) is cur-
rently being used for the treatment of secondary hyper-Key words: secondary hyperparathyroidism, PTH, uremia, calcitriol
analogs, vitamin D, chronic renal failure, hemodialysis. parathyroidism in patients maintained on hemodialysis.
Recently, another vitamin D analog, doxercalciferolReceived for publication October 8, 2001
[1-hydroxyvitamin D2 (1D2); Hectorol], also has beenand in revised form May 9, 2002
Accepted for publication May 13, 2002 shown to be effective in reducing plasma PTH levels in
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hyperparathyroidism [25, 26]. In contrast to 19-nor, this Heat muffle oven (Blue M Corporation, Blue Island, IL,
compound is a pro-hormone and must be activated by USA). The ash was dissolved in concentrated hydrochlo-
the liver by the addition of a hydroxyl group at carbon ric acid and analyzed for calcium and phosphorus. Prior
25 before this vitamin D analog is active. The purpose to the study, the diet also was analyzed for calcium and
of the present study was to compare, in normal and phosphorus using the same method. The net amount of
uremic rats, the calcemic and phosphatemic effects of intestinal calcium or phosphorus absorbed was expressed
these two vitamin D analogs, 19-nor and 1D2. as the percent of ingested calcium or phosphorus not
appearing in the feces.
METHODS
Calcemic response to 19-nor-1,25-(OH)2D2 and
Effects of 19-nor-1,25-(OH)2D2 and 1(OH)D2 1(OH)D2 in parathyroidectomized rats
on plasma calcium, phosphorus and parathyroid
Normal parathyroidectomized (PTX) rats were usedhormone in uremic rats
in this study to eliminate the effects of 19-nor and 1D2Renal insufficiency was induced in a group of 66 fe- on PTH synthesis and secretion, and to provide a wider
male Sprague-Dawley rats by 5/6 nephrectomy. This pro-
range of calcium levels in which to evaluate these two
cedure involves the ligation of most of the branches of
compounds. Parathyroid glands were removed microsur-the left renal artery followed by right nephrectomy. The
gically from a group of 15 female Sprague-Dawley ratsanimals were divided into seven groups. Group 1 re-
weighing 225 to 250 grams. Rats were fasted overnight andceived vehicle and served as the uremic control group.
blood was drawn to confirm parathyroidectomy. OnlyGroups 2, 3, and 4 received 50, 100, or 250 ng of 19-nor,
animals with a plasma total calcium less than 7 mg/dLrespectively, intraperitoneally three times a week for two
were used in this study. A diet deficient in calcium wasweeks, and groups 5, 6, and 7 received, 50, 100, or 250
used to eliminate the contribution of intestinal absorp-ng of 1D2 intraperitoneally three times a week for two
tion to plasma calcium levels. Parathyroidectomized ratsweeks. Six normal rats served as the normal control. At
were fed a diet containing 0.02% calcium and 0.35%the end of the study the animals were euthanized and
phosphorus and received daily intraperitoneal injectionsblood was obtained for total and ionized calcium, phos-
of vehicle (propylene glycol), or 100 ng of 19-nor or 1D2phorus, creatinine and parathyroid hormone. The rats
for a period of 35 days. Blood was obtained from thewere fed a rodent chow containing 0.9% calcium and
tail every two to three days for the first 11 days and then0.55% phosphorus.
at days 18 and 35 for plasma calcium determinations.
Metabolic studies in normal rats
Phosphatemic response to 19-nor-1,25-(OH)2D2 andBlood was drawn from the tail of 28 normal female
1(OH)D2 in parathyroidectomized ratsSprague-Dawley rats weighing 225 to 250 grams for the
determination of plasma calcium and phosphorus. The Studies were performed as described in the last section
animals were then divided into four groups and placed of this article, except that in this study a group of 23
in group housing, and treatment was begun. The rats PTX rats were fed a phosphorus deficient diet (0.02%
received daily injections of (1) vehicle (100L propylene phosphorus, 0.5% calcium). In addition, the rats received
glycol), (2) 10 ng of 1,25-(OH)2D3, (3) 100 ng of 19-nor, daily intraperitoneal injections of vehicle (propylene gly-
or (4) 100 ng of 1D2 for 14 days, and were given free col) or 200 ng of 19-nor or 1D2 for a period of 10 days.
access to deionized water and normal rodent chow con- Blood samples were obtained from the tail as previously
taining 0.90% calcium and 0.55% phosphorus. We chose described on days 0, 2, 4, 6, 8, and 11 for plasma phospho-
the same dose of 19-nor and 1D2 for comparison. The rus determinations.
dose of 1,25-(OH)2D3 was derived from previous studies.
On the last four days of treatment the rats were placed Analytical determinations
in metabolic cages. Twenty-four hour urine and feces
Total calcium was measured using an atomic absorp-were collected and daily dietary intake monitored. Re-
tion spectrophotometer (model 1100B; Perkin-Elmer,sults are taken from the mean of the last three days of
Norwalk, CT, USA). Ionized calcium was measured us-treatment. At the end of the study, rats were euthanized
ing an ionized specific-calcium electrode (model ICA-1;and blood was taken for the measurement of ionized
Radioneter, Copenhagen, Denmark). Plasma creatinine,calcium, total calcium and phosphorus. The urine was
blood urea nitrogen (BUN) and phosphorus were deter-acidified and each 24-hour urine sample was analyzed
mined by autoanalyzer (Mira Plus; COBAS, Branch-for calcium and phosphorus. Urinary excretion is ex-
burg, NJ, USA). Intact PTH was measured using a immu-pressed as total calcium or phosphorus excreted in mg
noradiometric assay specific for rat PTH (Immutopics,per 24 hours. Feces for each 24-hour period were dried
in a drying oven at 100C and ashed overnight in a Lab San Clemente, CA, USA).
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Table 1. Blood chemistries in normal and uremic rats
Cr T Ca ICa P
Group N mg/dL PTH pg/mL
Normal 6 0.780.05 8.960.08 4.460.07 5.770.29 50.313.2
Uremic control 9 1.160.04 9.020.13 4.620.13 7.480.93 185.4114.8
U19-nor (50 ng) 10 1.330.05 9.230.09 4.610.08 6.470.65 76.316.6
U19-nor (100 ng) 10 1.280.03 9.300.12 4.570.08 5.240.24a 58.29.4
U19-nor (250 ng) 10 1.170.06 9.510.12a 4.630.05 6.720.70 54.614.0
U1-D2 (50 ng) 9 1.500.20 9.790.17b 4.760.08 6.620.71 138.944.1d
U1-D2 (100 ng) 9 1.440.06 11.870.20c 5.460.09c 7.940.31 2
U1-D2 (250 ng) 9 1.810.08 12.100.20c 5.340.16c 9.540.51a 2
a P  0.05 from uremic control
b P  0.01 from uremic control
c P  0.001 from uremic control
d P  0.01 from 19-nor (50 mg)
Material and reagents
1D2 was provided by Dr. Hector DeLuca (Madison,
WI, USA), 1,25-(OH)2D3 was supplied by Dr. Milan
Uskokovic (Hoffman LaRoche, Nutley, NJ, USA) and
19-nor-1,25-(OH)2D2 was provided by Abbott Pharma-
ceuticals (Abbott Park, IL, USA). We greatly appreciate
their generosity. Normal rodent chow was manufactured
by Ralston Purina, Inc., (#5001; St. Louis, MO, USA)
and the calcium-and phosphorus-deficient diets were
purchased from Dyets Inc. (Bethelem, PA, USA).
Statistical analysis
All results are expressed as mean  SEM. One way
analysis of variance (ANOVA) was used for comparison Fig. 1. Effects of vehicle, 19-nor-1,25-(OH)2D2 (50,100, or 250 ng) and
between groups and non-paired t test was used to com- 1(OH)D2 (50,100, or 250 ng) on the Ca  P product in uremic rats.
Rats were treated IP, 3  week for 2 weeks. No dose of 19-nor-1,25-pare normal rats with each uremic group.
(OH)2D2 affected the Ca  P product ( , N  10) while 1(OH)D2
caused a progressive increase in the Ca  P product ( , N  9). *P 
0.01 vs. control rats; **P  0.001 vs. control rats.
RESULTS
Effects of 19-nor-1, 25-(OH)2D2 and 1(OH)D2
in uremic rats
normal rats (50.3  13.2 pg/mL). Although completeTable 1 shows the effects of two weeks of treatment
suppression of PTH (2 pg/mL) was seen in rats treatedwith 19-nor or 1D2 on plasma creatinine, ionized cal-
with 100 and 250 ng of 1D2, this was accompanied bycium, phosphorus and PTH in the uremic rats. The ad-
a marked increase in plasma-ionized calcium (1D2100ministration of 19-nor (50, 100,or 250 ng) did not increase
ng, 5.46  0.09 mg/dL and 1D2 250 ng, 5.34  0.16ionized calcium or phosphorus. On the other hand, the
mg/dL vs. uremic control, 4.62 0.13 mg/dL, P 0.001).administration of the same dose of 1D2 produced a
By comparison, the same dose of 19-nor (100 ng) sup-dose dependent increase in both blood chemistries.
pressed the increase in PTH seen in the uremic controlThe administration of 50 ng of 19-nor suppressed the
group by almost 70% (58.2  9.4 pg/mL) but did notincrease in PTH seen in uremic rats treated with vehicle
increase plasma ionized calcium (4.57  0.08 mg/dL) oralone (19-nor, 76.3  16.0 pg/mL versus uremic control,
phosphorus (5.24  0.24 mg/dL).185  115 pg/mL). The same dose of 1D2, however,
Examination of the Ca  P product (Fig. 1) revealeddid not significantly suppress the increase in PTH
that none of the doses of 19-nor increased this parameter(138.9 41.1 pg/mL). The PTH level in rats treated with
above that seen in the uremic control group (control,the 50 ng dose of 19-nor was significantly lower than
67.2 7.9; 19-nor 50 ng, 59.6 5.9; 19-nor 100 mg, 48.7that of rats treated with the 50 ng dose of 1D2 (P 
2.3; 19-nor 250 mg, 64.3 7.2 mg2/dL2). In contrast, both0.01). In addition, PTH levels in rats treated with 100 ng
the 100 ng and 250 ng doses of 1D2 caused a markedor 250 ng of 19-nor (100 ng, 58.2  9.4 pg/mL; 250 ng,
54.6  14.0 pg/mL) were not different from those of increased in the Ca  P product (100 ng, 94.6  4.8 mg2/
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Fig. 2. Effects of vehicle, 1,25-(OH)2D3 (10 ng), 19-nor-1,25-(OH)2D2 Fig. 3. Effects of vehicle, 1,25-(OH)2D3 (10 ng), 19-nor-1,25-(OH)2D2
(100 ng) and 1(OH)D2 (100 ng) on intestinal calcium absorption in (100 ng) and 1(OH)D2 (100 ng) on intestinal phosphorus absorption
normal rats. The administration of 10 ng of 1,25-(OH)2D3 (, N  7) in normal rats. The administration of 10 ng of 1,25-(OH)2D3 (, N 
or 100 ng of 1(OH)D2 ( , N  7) for 14 days produced a significant 7) or 100 ng of 1(OH)D2 ( , N 7) for 14 days produced a significant
increase in intestinal calcium absorption compared to control rats re- increase in intestinal phosphorus absorption compared to control rats
ceiving vehicle alone (, N  7; P  0.01) or to rats receiving 100 ng receiving vehicle alone (, N  7; P  0.01) or to rats receiving 100
of 19-nor-1,25-(OH)2D2 ( , N  7; P  0.05). On the other hand, ng of 19-nor-1,25-(OH)2D2 ( , N  7; P  0.01). In addition, the
the administration of 19-nor-1,25-(OH)2D2 did not increase intestinal administration of 19-nor-1,25-(OH)2D2 did not increase intestinal phos-
calcium absorption compared to control rats. *P 0.01 vs. control rats; phorus absorption compared to control rats alone. *P 0.01 vs. control
†P  0.01 vs. 19-nor-treated rats. rats; †P  0.01 vs. 19-nor-treated rats.
dL2, P  0.01; and 250 ng, 115.6  6.7 mg2/dL2, P 
0.001).
Metabolic studies in normal rats
The effects of 1,25-(OH)2D3 (10 ng), and 100 ng of
19-nor or 1D2 on the intestinal absorption of calcium
and phosphorus and on the urinary excretion of calcium
and phosphorus were studied in a group of normal rats.
The intestinal absorption of calcium increased from
23.9  2.30% in control rats to 32.8  1.34% in rats re-
ceiving 1,25-(OH)2D3, to 27.1  1.11% in rats treated
with 19-nor and to 32.7 2.15% after the administration Fig. 4. Effects of vehicle, 1,25-(OH)2D3 (10 ng), 19-nor-1,25-(OH)2D2
(100 ng) and 1(OH)D2 (100 ng) on urinary calcium excretion in normalof 1D2 (Fig. 2). The intestinal calcium absorption seen
rats. The administration of 10 ng of 1,25-(OH)2D3 (, N  7) or 100after the administration of both 1,25-(OH)2D3 and 1D2 ng of 1(OH)D2 ( , N  7), for 14 days produced a marked increasewas significantly higher than that of rats receiving vehicle in urinary calcium excretion compared to control rats receiving vehicle
alone (, N  7) (P  0.01). While the 100 ng of 19-nor-1,25-(OH)2D2alone (P 0.01). The intestinal calcium absorption after
( , N  7) produced a modest increase in urinary calcium excretiontreatment with 19-nor was not statistically different than
compared to the control group (P 0.05) this increase was significantly
that of control rats. less than that seen in rats receiving either 1,25-(OH)2D3 (P  0.01) or
the same dose of 1(OH)D2 (P  0.001). *P  0.05 vs. control rats;Similar effects were observed with intestinal phospho-
**P  0.01 vs. control rats. ***P  0.001 vs. control rats; †P  0.01rus absorption (Fig. 3). Intestinal absorption of phospho-
vs. 19-nor-treated rats; and ††P  0.001 vs. 19-nor-treated rats.
rus increased significantly in 1,25D-treated rats (44.7 
1.14%, P 0.01) and in rats receiving 1D2 (45.0 1.6%,
P  0.01) compared to vehicle-treated rats (36.1 
1.8%). The administration 19-nor had no effect on intes- increased urinary calcium excretion to 21.9 2.5 mg/24 h
(P 0.01). The urinary calcium in 1D2 treated rats wastinal phosphorus absorption (37.7  1.58%). The in-
crease in phosphorus absorption seen after treatment similar to that seen in 1,25-(OH)2D3 treated rats. The
urinary calcium excretion in 19-nor-treated rats, how-with 1,25-(OH)2D3 or 1D2 were significantly greater
(P  0.01) than that of 19-nor-treated rats. ever, was significantly less than that seen with either
1,25-(OH)2D3 (P  0.01) or 1D2 treatment (P  0.01).As shown in Figure 4, 24-hour urinary calcium excre-
tion increased from 4.46  0.39 mg/24 h in control rats Figure 5 shows that 24-hour urinary phosphorus in-
creased from 5.37  1.14 mg/24 h in the control groupto 17.9  1.36 mg/24 h (P  0.01) after treatment with
1,25-(OH)2D3, while 19-nor induced a more modest in- to 20.7  2.4 mg/24 h (P  0.01) with 1,25-(OH)2D3
treatment, to 24.7  2.7 mg/24 h (P  0.01) in ratscrease on urinary calcium excretion (10.5 1.25 mg/24 h,
P  0.05). In contrast to 19-nor, administration of 1D2 receiving 1D2, but only to 10.9  1.21 mg/24 h (NS) in
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Fig. 5. Effects of vehicle, 1,25-(OH)2D3 (10 ng), 19-nor-1,25-(OH)2D2 Fig. 6. Comparison of the calcemic response of 19-nor-1,25-(OH)2D2
(100 ng) and 1(OH)D2 (100 ng) on urinary phosphorus excretion in (100 ng) and 1(OH)D2 (100 ng) in PTX rats fed a calcium-deficient
normal rats. The administration of 10 ng of 1,25-(OH)2D3 (, N  7) diet. The administration of 100 ng of 19-nor-1,25-(OH)2D2 produced
or 100 ng of 1(OH)D2 ( , N  7) for 14 days produced a marked less of an increase in plasma calcium than did the same dose of
increase in urinary phosphorus excretion compared to control rats re- 1(OH)D2. Rats received IP injections of vehicle (propylene glycol; ,
ceiving vehicle alone (, N  7; P  0.001). On the other hand, the N  4), 19-nor-1,25-(OH)2D2 (, N  6), or 1(OH)D2 (, N  5)
administration of 100 ng of 19-nor-1,25-(OH)2D2 ( , N  7) did not daily for 35 days. *P 0.05 vs. 19-nor-1,25-(OH)2D2-treated rats; **P
increase urinary phosphorus excretion compared to control rats. In 0.01 vs. 19-nor-1,25-(OH)2D2-treated rats; and ***P  0.001 vs. 19-nor-
addition, the increase in urinary phosphorus excretion in both the 1,25- 1,25-(OH)2D2-treated rats.
(OH)2D3 (P 0.01) and 1(OH)D2-treated (P 0.001) rats was signifi-
cantly greater than in those receiving 19-nor-1,25-(OH)2D2. *P  0.001
vs. control rats; †P  0.01 vs. 19-nor-treated rats; and ††P  0.001 vs.
19-nor-treated rats.
the 19-nor treated rats. As with urinary calcium, the
increase in urinary phosphorus was not different between
1,25D and 1D2 treated rats, but both of these groups
had greater urinary P excretion compared to 19-nor (P
0.01 and P  0.001, respectively). Plasma total calcium
was higher in the 1D2 treated group compared to
19-nor-treated rats (10.9  0.19 vs 10.1  0.07 mg/dL).
Plasma ionized Ca and phosphorus were similar in both
Fig. 7. Comparison of the phosphatemic response of 19-nor-1,25-groups (date, not shown).
(OH)2D2 (200 ng) and 1(OH)D2 (200 ng) in PTX rats fed a phosphate-
deficient diet. The administration of 200 ng of 19-nor-1,25-(OH)2D2
Calcemic and phosphatemic responses of normal produced less of an increase in plasma phosphorus than did the same
dose of 1(OH)D2. Rats received IP injections of vehicle (propylenePTX rats to 19-nor and 1D2
glycol; , N  7), 19-nor-1,25-(OH)2D2 (, N  8), or 1(OH)D2 (,
The calcemic and phosphatemic effects of 19-nor and N  8) daily for 11 days. *P  0.05 vs. 19-nor-1,25-(OH)2D2-treated
rats; **P 0.01 vs. 19-nor-1,25-(OH)2D2-treated rats; and ***P 0.0011D2 were compared in PTX rats treated daily with ei- vs. 19-nor-1,25-(OH)2D2-treated rats.ther compound. After 35 days, total plasma calcium had
increased from 5.33  0.30 to 8.29  0.32 mg/dL in
19-nor-treated rats while 1D2 induced a greater re-
5.66  0.25 mg/dL with 19-nor treatment, but to 8.61 sponse, increasing plasma calcium from 5.35  0.38 to
0.59 mg/dL with 1D2 administration (P  0.01).10.1  0.15 mg/dL over the same time period (Fig. 6).
The increase in plasma calcium was significantly greater
in 1D2 treated rats than in those receiving 19-nor (P  DISCUSSION
0.001). Plasma calcium in vehicle-treated rats remained Chronic renal failure (CRF) is characterized by changes
unchanged during the course of the study. in mineral homeostasis, with secondary hyperparathy-
The phosphatemic response to 19-nor and 1D2 is roidism (SH) appearing even in the early stages of renal
shown in Figure 7. As expected, serum phosphorus ini- insufficiency leading to the development of renal osteo-
tially increased after PTX from 7.14  0.39 to 10.7  dystrophy [27–29]. Thus, controlling SH has been a pri-
0.29 mg/dL. Thereafter the rats were fed a phosphate mary goal in the treatment patients with CRF.
deficient diet and started on 200 ng daily of 19-nor or The 1,25-(OH)2D3 analog, 19-nor-1,25-(OH)2D2 is cur-
1D2. By the eleventh day of treatment serum phospho- rently being used in the treatment of SH because it re-
tains the ability of the parent compound to effectivelyrus increased from 4.93  0.20 mg/dL in control rats to
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suppress PTH, but produces significantly less hypercalce- resorption of Ca and P by these two analogs. These studies
also showed 1D2 to be more potent than 19-nor in mobi-mia and hyperphosphatemia, providing a larger thera-
peutic window in which to treat patients. In a 12-week lizing Ca and P from bone at equivalent doses.
While little is known about the mechanism of actionmulti-center clinical trial, Martin et al reported a 60%
decrease in serum PTH in hemodialysis patients receiv- of 1D2, it is not surprising that it would have more
potent calcemic and phosphatemic properties than 19-ing 19-nor compared to those receiving placebo [30]. In
their study, mean serum calcium increased slightly in nor. Unlike 19-nor, 1D2 is a pro-hormone and first must
be activated. This activation occurs in the liver by the19-nor-treated patients, although the difference was not
statistically significant. While 19-nor and 1,25D were not addition of a hydroxyl group at carbon 25 producing the
active compound 1,25-(OH)2D2. 1,25-(OH)2D2 has beendirectly compared, the results of Martin et al have led
to widespread use of 19-nor for SH in patients on hemo- shown to have the same potency as 1,25-(OH)2D3 in
stimulating intestinal calcium transport and bone mineraldialysis.
Recently another vitamin D analog, 1(OH)D2 (1D2) mobilization [33, 34]. In addition, a recently published
study using the mouse bone marrow culture model com-also has been used for the treatment of SH. Comparative
studies between oral and IV administration of 1D2 in pared the bone resorbing activities of 1,25-(OH)2D3,
1,25-(OH)2D2, and 19-nor(OH)2D2 [35]. In that study,patients with CRF indicate that both modes of treatment
suppress PTH, although the degree of hypercalcemia and 1,25-(OH)2D3 and 1,25-(OH)2D2 had the same activity
while the bone-resorbing activity of 19-nor(OH)2D2 washyperphosphatemia is greater with the oral preparation
[26]. Since to our knowledge no studies have compared 70% less. Since osteoblasts and not osteoclasts express
the vitamin D receptor (VDR), it was thought that therethe efficacy of 19-nor and 1D2 in treating SH, we com-
pared the effect of these two compounds on plasma cal- must be some factor(s) responsible for communication
between these two cell types triggering osteoclastic bonecium, phosphorus and PTH in uremic rats and on intesti-
nal Ca and P absorption and bone resorption in normal resorption. Recent studies have identified this protein
as osteoprotegerin ligand (OPGL or RANKL) [36–38].and PTX rats.
We first compared the ability of these two analogs to Holiday et al found that 19-nor, although seemingly as
potent as 1,25-(OH)2D3 in osteoclast recruitment, wassuppress PTH in uremic rats. 19-nor suppressed PTH
and without changes in serum ionized Ca or P, while less active in osteoclast activation [35]. The comparative
effect of 19-nor on RANKL production is not known,1D2 suppressed PTH only at doses where a marked in-
crease in serum Ca and P occurred. However, it is possi- but recently Lacey et al found that a higher concentration
of OPGL is required for osteoclast activation than forble that on intermediate doses of 1D2, that is, 75 ng,
could suppress serum PTH with little effect on serum osteoclast recruitment [36]. One possible explanation for
the decreased osteoclast activity of 19-nor is that 19-norcalcium. Earlier in vitro studies from our laboratory
showed that 19-nor can suppress PTH secretion in cul- may induce RANKL to levels high enough for the re-
cruitment of osteoclasts but not for their activation. Thistured bovine parathyroid cells with the same potency as
1,25-(OH)2D3 [23]. Although 19-nor is hypercalcemic at hypothesis requires further experimental confirmation.
Our current study compares equal doses of 19-norvery high doses, it was also shown to suppress PTH levels
in uremic rats at doses that did not affect serum Ca or (OH)2D2 and 1(OH)D2. It is likely that even though
19-nor(OH)2D2 is less calcemic than 1(OH)D2, serumP levels [23, 24].
To further evaluate the higher calcemic response by levels of active hormone are higher in the 19-nor
(OH)2D2–treated group than in rats receiving 1D2, since1D2, we assessed the effects of the two compounds on
intestinal calcium absorption and bone mineral mobiliza- 1(OH)D2 must first be converted to 1,25-(OH)2D2. The
rate of conversion of 1D2 to 1,25-(OH)2D2 is not known,tion. Previous studies from our laboratory comparing
1,25-(OH)2D3 and 19-nor showed 19-nor to be about 10 but is probably similar to the rate of conversion of
1(OH)D3 to 1,25-(OH)2D3 since the liver enzyme re-times less effective than 1,25(OH)2D3 both in increasing
intestinal Ca and P absorption [31] and in mobilizing Ca sponsible for this conversion, cytochrome p450, appears
not differentiate between 1(OH)D2 and 1(OH)D3 [39].and P from bone [32]. Our current study repeated these
earlier studies comparing 19-nor and 1D2. In metabolic In standard bioassays 1(OH)D2 has been shown to
be as effective as 1(OH)D3 but is 5- to 15-fold lessstudies 19-nor was significantly less potent in increasing
both intestinal Ca and P absorption than 1D2. In addi- toxic than 1(OH)D3 in vivo [40, 41]. Studies by Horst,
Koszewski and Reinhardt give possible insight into thetion, there was significantly less urinary Ca and P excre-
tion with the 19-nor treatment. For bone resorption stud- difference in toxicity between vitamin D2 and vitamin
D3 [42]. Under physiological conditions they showed thaties, PTX rats treated with either analog were fed diets
deficient in either Ca or P. This was done to eliminate any the predominant monohydroxylated form of vitamins D2
and D3 is 25-(OH)D, but that in vitamin D2-treated ratscontribution of intestinal Ca or P absorption to serum
Ca or P, allowing for an indirect measurement of bone approximately 20% is 24-(OH)D2. In contrast, when the
Slatopolsky et al: 19-nor and 1D2 in uremia 1283
same dose of vitamin D3 was given, 24-(OH)D3 could ACKNOWLEDGMENTS
not be detected. 24-(OH)D2 has twofold less affinity for This study was supported in part by a Washington University grant,
Research in Renal Diseases, and by Abbott Pharmaceuticals.the VDR and is less toxic than 25-(OH)D3 [39]. In addi-
tion, Mawer et al demonstrated that vitamin D2 and not Reprint requests to Eduardo Slatopolsky, M.D., Renal Division, Box
vitamin D3 can be converted to 1,24-(OH)2D2 [43]. This 8126, Department of Internal Medicine, 660 South Euclid Avenue, St.
Louis, Missouri 63110, USAmetabolite has potent cell differentiating activity, but
E-mail: eslatopo@im.wustl.edulower calcemic activity than either 1,25-(OH)2D2 or
1,25-(OH)2D3. It has been proposed that 1D2 may be REFERENCES
24-hydroxylated in target cells to produce an active me-
1. Silver J, Russell J, Sherwood LM: Regulation by vitamin Dtabolite, 1,24-(OH)2D2, which is less toxic. This hypothe- metabolites of messenger RNA for pre-pro-parathyroid hormone
sis remains to be tested. in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:
4270–4273, 1985There also is evidence in the literature that vitamin
2. Russell JD, Lettieri D, Sherwood LM: Suppression by 1,25-D analogs can bind differently than 1,25-(OH)2D3 to the (OH)2D of transcription of the parathyroid hormone gene. Endo-
VDR producing a conformational change in the VDR crinology 119:2864–2866, 1985
3. Cantley LK, Russell J, Lettieri D, et al: 1,25-Dihydroxyvitaminmolecule that favors the selective recruitment of nuclear
D3 suppresses PTH secretion from bovine parathyroid cells in tissuetranscriptional co-activators resulting in a variable de- culture. Endocrinology 117:2114–2119, 1985
4. Chan YL, McKay C, Dye E, et al: The effect of 1,25-dihydroxycho-gree of VDR-mediated transcription [44–47]. The bind-
lecalciferol on parathyroid hormone secretion by monolayer cul-ing of 19-nor and 1,25-(OH)2D2, the active metabolite tures of bovine parathyroid cells. Calcif Tissue Int 38:27–32, 1986
of 1D2, to the VDR could result in the recruitment of 5. Slatopolsky E, Weerts C, Thielan J, et al: Marked suppression
of secondary hyperparathyroidism by intravenous administrationdifferent co-activators.
of 1,25-dihydroxycholecalciferol in uremic patients. J Clin InvestOur current studies in uremic animals treated with 74:2136–2143, 1984
19-nor or 1D2 demonstrate that 1D2 also produces a 6. Delmez JA, Tindira C, Grooms P, et al: Parathyroid hormone
suppression by intravenous 1,25-dihydroxyvitamin D: A role formarked increase in the Ca  P product at doses where
increased sensitivity to calcium. J Clin Invest 83:1349–1355, 1989
19-nor has no effect. Cardiovascular problems, including 7. Andress DL, Keith MD, Norris C, et al: Intravenous calcitriol
in the treatment of refractory osteitis fibrosa of chronic renal fail-vascular calcification, are the most frequent cause of
ure. N Engl J Med 321:274–279, 1989death in patients with CRF [48, 49]. Traditionally a Ca 8. Gallieni M, Brancaccio D, Padovese P, et al: Low-dose intrave-
P product of 75 mg2/dL2 has been the target in treating nous calcitriol treatment of secondary hyperparathyroidism in he-
modialysis patients. Kidney Int 42:1191–1198, 1992patients with CRF. Recently, however, studies reveal
9. Cannella G, Bonucci E, Rolla D, et al: Evidence of healing of
that patients with a Ca  P product above 55 to 60 mg2/ secondary hyperparathyroidism in chronically hemodialyzed ure-
mic patients treated with long-term intravenous calcitriol. KidneydL2 tend to have vascular calcification while those below
Int 46:1124–1132, 1994do not [50–52]. Thus, the recommended Ca  P product
10. Slatopolsky E, Weertz C, Lopez-Hilker S, et al: Calcium carbon-
has been substantially lowered [53]. Our studies show ate as a phosphate binder in patients with chronic renal failure
undergoing dialysis. N Engl J Med 315:157–161, 1986that the effect of 19-nor on the Ca  P product is mark-
11. Bikle DD: Clinical counterpoint: Vitamin D: New actions, newedly less than that of 1D2, which could have significant analogs, new therapeutic potential. Endocrine Rev 13:765–784, 1992
12. Brown AN, Dusso A, Slatopolsky E: Selective vitamin D analogsbiological consequences.
and their therapeutic applications. Semin Nephrol 14:156–174, 1994In summary, we demonstrate significant differences in
13. Norman AW: The vitamin D endocrine system: Manipulation of
calcium and phosphate metabolism in normal and uremic structure-function relationships to provide opportunities for devel-
opment of new cancer chemopreventive and immunosuppressiverats receiving 1,25-(OH)2D3, 19-nor 1,25-(OH)2D2 and
agents. J Cell Biochem 22:S218–S225, 19951(OH)D2. The current study aimed to determine the 14. Ostrem VK, Tanaka Y, Prahl J, et al: 24- and 26-homo-1,25-
difference between the two vitamin D analogs. It seems dihydroxyviatmin D3: Preferential activity in inducing differentia-
tion of human leukemia cells HL-60 in vitro. Proc Natl Acad Scifrom the results obtained in normal and PTX rats that
USA 84:2610–2614, 1987
there is a significant difference in the absorptive and 15. Binderup L, Bramm E: Effects of a novel vitamin D analogue
MC903 on cell proliferation and differentiation in vitro and onresorptive properties of these two analogs. In these rats,
calcium metabolism in vivo. Biochem Pharmacol 37:889–895, 19881D2 has a greater effect at the level of both the skeleton 16. Zhou JY, Norman AW, Lubbert M, et al: Novel vitamin D analogs
and intestinal tract when compared with 19-nor. Similar that modulate leukemic cell growth and differentiation with little
effect on either intestinal calcium absorption or bone calcium mobi-effects were observed in uremic animals with increased
lization. Blood 74:82–93, 1989
levels of parathyroid hormone. Although both com- 17. Morimoto S, Imanaka S, Koh E, et al: Comparison of the inhibi-
tions of proliferation of normal and psoriatic fibroblasts by 1,25-pounds were effective in suppressing PTH, 1D2 induced
dihydoxyvitamin D3 and synthetic analogues of vitamin D3 with ansignificant increases in the Ca  P product. If the differ-
oxygen atom in their side chain. Biochem Int 19:1143–1149, 1989
ential metabolic effects of 19-nor and 1D2 were mir- 18. Chen TC, Persons K, Uskokovic MR, et al: An evaluation of 1,25-
dihydroxyvitamin D3 analogues on the proliferation and differenti-rored in humans, the effects likely would be clinically
ation of cultured human keratinocytes, calcium metabolism, and thesignificant. Further studies in patients are necessary to differentiation of human HL-60 cells. J Nutr Biochem 4:49–57, 1993
19. Abe J, Nakano T, Nishii Y, et al: A novel vitamin D3 analog,define these differences.
Slatopolsky et al: 19-nor and 1D2 in uremia1284
22-oxa-1,25-dihydoxyvitamin D3, inhibits the growth of human cytokine that regulates osteoclast differentiation and activation.
Cell 93:165–176, 1998breast cancer in vitro and in vivo without causing hypercalcemia.
Endocrinology 129:832–837, 1991 37. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation
factor is a ligand for osteoprotegerin/osteoclasto-genesis-inhibitory20. Oikawa T, Yoshida Y, Shimamura M, et al: Antitumor effect of
22-oxa-1,25-dihydoxyvitamin D3, a potent angiogenesis inhibitor, factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci
USA 95:3597–3602, 1998on rat mammary tumors induced by 7,12-dimethylbenz[a]-anthra-
cene. Anticancer Drugs 2:475–480, 1991 38. Fuller K, Wong B, Choi YW, et al: TRANCE is necessary and
sufficient for osteoblast-mediated activation of bone resorption in21. Colston KW, Chander SK, Mackay AG, et al: Effects of synthetic
vitamin D analogues on breast cancer cell proliferation in vivo osteoclasts. J Exp Med 188:997–1001, 1998
39. Horst RL: Metabolism of vitamins D2 and D3, in Vitamin D, editedand in vitro. Biochem Pharmacol 44:693–702, 1992
22. Abe J, Takita Y, Nakano T, et al: A synthetic analogue of vitamin by Feldman D, Glorieux F, Pike W, San Diego, Academic Press,
1997, pp 13–32D3, 22-oxa-1,25-dihydoxyvitamin D3, is a potent modulator of in
vivo immunoregulating activity without inducing hypercalcemia in 40. Harrington DD, Page EH: Acute vitamin D3 toxicosis in horses:
Case reports and experimental studies of the comparative toxicitymice. Endocrinology 124:2545–2647, 1989
of vitamins D2 and D3. J Am Vet Med Assoc 182:1358–1369, 198923. Slatopolsky E, Finch J, Ritter C, et al: A new analog of Calcitriol,
41. Sjo¨den G, Smith C, Lingren U, et al: 1--Hydroxyvitamin D2 is19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion
less toxic than 1--hydroxyvitamin D3 in the rat. Proc Soc Expin uremic rats in the absence of hypercalcemia. Am J Kid Dis 26:
Biol Med 178:432–436, 1985852–860, 1995
42. Horst R, Koszewski NJ, Reinhardt TA: 1--Hydroxylation of24. Takahashi F, Finch JL, Denda M, et al: A new analogue of 1,25-
24-hydroxyvitamin D2 represents a minor physiological pathway(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses PTH and parathyroid
for the activation of vitamin D2 in mammals. Biochemistry 29:578–gland growth in uremic rats without elevation of intestinal vitamin
582, 1990D receptor content. Am J Kid Dis 30:105–112, 1997
43. Mawer EB, Jones G, Davies M, et al: Unique 24-hydroxylated25. Tan AU Jr, Levine BS, Mazess RB, et al: Effective suppression
metabolites represent a significant pathway of metabolism of vita-of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodi-
min D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvita-alysis patients with moderate to severe secondary hyperparathy-
min D2 detectable in human serum. J Clin Endocrin Metabol 83:roidism. Kidney Int 51:317–323, 1997
2156–2166, 199826. Maung HM, Elangovan L, Frazao JM, et al: Efficacy and side
44. Peleg S, Sastry M, Collins ED, et al: Distinct conformationaleffects of intermittent intravenous and oral doxercalciferol (1-
changes induced by 20-epi analogues of 1,25-dihydroxyvitamin D3hydrovitamin D2) in dialysis patients with secondary hyperparathy- are associated with enhanced activation of the vitamin D receptor.roidism: A sequential comparison. Am J Kid Dis 37:532–543, 2001
J Biol Chem 270:10551–10558, 199527. Ritz E, Schomig M, Bommer J: Osteodystrophy in the millennium.
45. Takeyama K, Masuhiro Y, Fuse H, et al: Selective interaction ofKidney Int 56(Suppl 73):S94–S98, 1999
vitamin D receptor with transcriptional coactivators by a vitamin28. Drueke TB: Renal osteodystrophy: Management of hyperphos-
D analog. Mol Cell Biol 19:1049–1055, 1999phatemia. Kidney Int 15:32–33, 2000
46. Yang W, Freedman LP: 20-Epi analogues of 1,25-dihydroxy-29. Hruska K: Pathophysiology of renal osteodystrophy. Pediatr vitamin D3 are highly potent inducers of DRIP coactivator com-Nephrol 14:636–640, 2000 plex binding to the vitamin D receptor. J Biol Chem 274:16838–30. Martin KJ, Gonzales EA, Gellens M, et al: 19-nor-1--25-dihy- 16848, 1999
droxyvitamin D2 (Paricalcitol) safely and effectively reduces the 47. Quack M, Carlberg C: Selective recognition of vitamin D receptor
levels of intact parathyroid hormone in patients on hemodialysis. conformations mediates promoter selectivity of vitamin D analogs.
J Am Soc Nephrol 9:1427–1432, 1998 Mol Pharmacol 55:1077–1087, 1999
31. Brown A, Finch JL, Slatopolsky E: The relative potencies of 48. US Renal Data System: USRDS 1999 Annual Data Report. Be-
1,25(OH)2D3 and 19-nor-1,25(OH)2D2 on intestinal calcium and thesda, The National Institutes of Health, National Institute of
phosphorus absorption. J Lab Clin Med 139:279–284, 2002 Diabetes and Digestive and Kidney Diseases, 1999
32. Finch JL, Brown AJ, Slatopolsky E: Differential effects of 1,25- 49. Bloembergen WE: Cardiac disease in chronic uremia. Epidemiol
dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on Adv Ren Replac Ther 4:185–193, 1997
calcium and phosphorus resorption in bone. J Am Soc Nephrol 10: 50. Huting J: Mitral valve calcification as an index of left ventricular
980–985, 1999 dysfunction in patients with end stage renal disease on peritoneal
33. DeLuca HF, Sicinski RR, Tanaka Y, et al: Biological activity of dialysis. Chest 105:383–388, 1994
1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3. Am J 51. Ribeiro S, Ramos A, Brandao A, et al: Cardiac valve calcification
Physiol 254:E402–E406, 1988 in haemodialysis patients: Role of calcium-phosphate metabolism.
34. Reinhardt TA, Ramberg CF, Horst RL: Comparison of receptor Nephrol Dial Transplant 13:2037–2040, 1998
binding, biological activity, and in vivo tracer kinetics for 1,25- 52. Andress DL: New therapies raise new issues for lowering para-
dihydroxyvitamin D3, 1,25-dihydroxyvitamin D2, and epimer. Arch thyroid hormone levels in uremic patients. Semin Dial 12:282–
Biochem Biophys 273:64–71, 1989 284, 1999
35. Holiday LS, Gluck S, Slatopolsky E, et al: 1,25-Dihydroxy-19- 53. Block GA, Port FK: Re-evaluation of risks associated with hyper-
nor-vitamin D2, a vitamin D analog with reduced bone resorbing phosphatemia and hyperparathyroidism in dialysis patients: Rec-
activity in vitro. J Am Soc Nephrol 11:1857–1864, 2000 ommendations for a change in management. Am J Kid Dis 6:1226–
1237, 200036. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a
